Partner with a proven kidney site.
Phase 1b, Phase 2a, Phase 2b, and Phase 3 trials, feasibility to closeout: one site, one accountable team, inside the largest private-practice nephrology group in the CSRA. Call to discuss feasibility; a CDA can be executed at any point.
Twenty-five years of trusted partnerships
SCRI has delivered Phase 1b, Phase 2a, Phase 2b, and Phase 3 studies for global pharma, emerging biotech, and device companies, and is the region's premier site for kidney research.
Phase 1b, Phase 2a, Phase 2b, and Phase 3.
From global pharma to emerging biotech and device companies.
Every Nephrology Associates physician. Board-certified, published in NEJM and leading journals.
Conducting clinical research for more than 25 years.
Everything a protocol needs, under one roof.
From CDA to closeout, SCRI runs as a single accountable site: dedicated specialists for budget and contract, regulatory, and patient coordination. The same people from your first feasibility call to database lock.
Budget & contract desk
Dedicated support for budget and contract negotiation, led by a Director of Research Operations with 20+ years of industry trial management.
Your central IRB, accepted
We work under the sponsor's central IRB. No local IRB, no duplicate review, no second calendar.
Certified Patient Coordinators
ACRP-certified patient coordinators with an average tenure of 7+ years pre-screen the Nephrology Associates population against your inclusion criteria and manage every study visit.
Regulatory Specialist
A dedicated regulatory specialist (CCRC) owns submissions, central IRB packets, and every study document. Regulatory is a job here, not a coordinator's spare hour.
On-site pharmacy & lab management
Investigational product handling and sample processing managed on site by a dedicated Pharmacy and Lab Manager.
Weekly research meeting
Investigators and coordinators meet weekly to review enrollment, screen failures, and protocol questions. Every open study, every week.
From first call to first patient.
A quick-start process with a named owner for each track. Feasibility, budget and contract, regulatory, and patient coordination run in parallel, not in sequence. Your central IRB is accepted, so there is no local review to wait on.
Talk directly with our Director of Research Operations about the indication, phase, enrollment target, and timeline. A CDA can be executed at any point.
Dedicated budget and contract support works the CTA while the regulatory specialist prepares the central IRB submission and site documents.
Investigators and coordinators trained on the protocol, pharmacy and lab set up, monitor space ready for your CRA.
The patient coordinator pre-screens the Nephrology Associates population; enrollment is reviewed at the weekly research meeting; one team stays with the study to closeout.
Certified, trained, audit-ready.
The certifications sponsors ask about first. Held, not promised.
- GCP-trained investigators and research staff
- CLIA-certified on-site laboratory
- ACRP-certified clinical research coordinators
- Sponsor's central IRB accepted
- Dedicated regulatory specialist (CCRC)
- Board-certified nephrologist investigators
Dedicated monitor space
A private monitoring room with its own restroom, so your CRA works uninterrupted for the whole visit.
On-site pharmacy and lab
Investigational product and sample processing handled on site, in the heart of Augusta's medical district.
A research facility, not a clinic corner
1521 Anthony Road is a dedicated research site, with research staff, a research schedule, and research space, drawing patients from seven Nephrology Associates offices.
Nephrology depth across the kidney-disease spectrum
Phase 1b, Phase 2a, Phase 2b, and Phase 3 trials across the kidney-disease spectrum.
Chronic Kidney Disease
Disease-modifying therapies aimed at slowing progression and protecting function across CKD stages.
Diabetic Kidney Disease
Agents that protect the diabetic kidney, including SGLT2 and non-steroidal MRA pathways.
Cardiorenal Protection
Studies at the intersection of heart and kidney disease, including elevated lipoprotein(a) and obesity outcomes.
Glomerular Disease
Investigational therapy for IgA nephropathy, lupus nephritis, and other immune-mediated kidney disease.
Anemia & Mineral Bone
Novel approaches to the anemia and mineral-bone complications of advanced kidney disease.
Hypertension
Trials targeting resistant and uncontrolled blood pressure, a principal driver of kidney decline.
Dialysis
Drug and device studies in hemodialysis and peritoneal dialysis: home hemodialysis, infection detection, anticoagulation.
Trusted by the sponsors writing the next chapter.
Sponsor partners over more than 25 years: global pharma, emerging biotech, and device companies.
What sponsors say
SCRI is the site you hope for on a nephrology program: investigators who see these patients every day, coordinators who know the protocol cold, and enrollment that arrives clean.
Eli Lilly and CompanyClinical Trial Manager
The population your protocol needs.
SCRI draws from the patient population of Nephrology Associates, PC, the largest private-practice nephrology group in the Central Savannah River Area, with seven offices across the region and physicians who serve as medical directors of area dialysis centers.
- Board-certified nephrologist investigators, led by Dr. Matthew Diamond, DO, FASN, FACP
- Investigators published in NEJM: SPRINT, DAPA-CKD, vadadustat
- Dedicated regulatory specialist; sponsor's central IRB accepted
- Dedicated budget and contract support, and a dedicated patient coordinator
- On-site pharmacy and laboratory management; private monitor space with restroom
- Weekly research meeting across every open study
The people on the other end of the call.
Katherine Peacock
Director of Research Operations. Joined SCRI in 2021 after 20+ years of industry trial management, directing trials from CDA execution through study closeout. Your feasibility contact, and the owner of the budget and contract desk.
Feasibility · Budget & ContractMeredith Prichard
Regulatory Coordinator and Certified Clinical Research Coordinator (ACRP). Manages every aspect of the site's regulatory process: central IRB submissions, site documentation, and ongoing compliance.
RegulatoryClinical Research Coordinators
ACRP-certified coordinators, each with more than two years of hands-on experience before certification, run patient coordination, from pre-screening to visits and retention, across every open protocol.
Patient CoordinationMaKayla Gore
Pharmacy and Lab Manager. Investigational product handling and sample processing on site, in the CLIA-certified laboratory.
Pharmacy & LabCall to discuss feasibility.
Talk directly with the people who run the site about the indication, phase, and timeline. A CDA can be executed at any point.
Bring us your protocol.
Prefer to start in writing? Tell us the indication, phase, and timeline. Feasibility requests go to the research operations team directly, not a form queue.
- Reply from the people who run the site
- CDA executed at any point
- Phase 1b, Phase 2a, Phase 2b, and Phase 3, drug and device
Ready to discuss your next study?
See if a study fits
Tell us a little about your kidney health and we will call you back. It costs nothing to ask.
Start here →Refer a patient
We screen against every open protocol and report the outcome back to your office, either way.
Refer now →Bring us your protocol
Call to discuss feasibility with a site that has delivered kidney trials for more than 25 years.
Call (706) 922-3005 →Southeastern Clinical Research Institute, LLC · 1521 Anthony Road, Augusta, Georgia 30904 · (706) 922-3005 · Fax (706) 722-5843
Two things worth reading
Written by the research team at the region's kidney research center, for patients, physicians, and sponsors alike.
Why a research institute owned by the treating nephrologists finds the patient, keeps the patient, and returns clean data. With the record to show for it.
Read the paper → From the blog Polycystic kidney disease: the research behind the first treatment, and Augusta's part in itWhat ADPKD is, what tolvaptan does, what comes next, and what families can do now.
Read the article →